Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors within the central anxious system, conolidine modulates alternate molecular targets. A Science Developments study discovered that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7